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A new target to control T cell responses involves de novo biosynthesis of tetrahydrobiopterin 
(BH4), adding to the list of processes dependent on BH4 synthesis, which includes 
neurotransmitter and nitric oxide production and pain control.    
 
T cells are the storm troopers of the immune system since they can kill other cells.  
Consequently, T cells must be licensed to expand and bear arms through a tightly regulated 
process 1. A recent study in Nature by Cronin et al. reveal a critical role for the enzyme cofactor 
tetrahydrobiopterin (BH4) in licensing T cell clones to proliferate and acquire weapons of 
destruction 2. These findings add to the extensive list of biological functions mediated by BH4, 
including production of neurotransmitters, nitric oxide and pain control. 
Circulating T cells are metabolically inert. On activation, T cells proliferate rapidly and acquire 
effector functions, including, in the case of cytotoxic T cells, the ability to destroy target cells (Fig. 
1). This licensing process has strict requirements for coordinated delivery of activation signals 
from antigens, co-stimulatory ligands and pro-inflammatory cytokines 1. These constraints 
ensure that potentially dangerous effector T cells are generated only as needed. Cronin et al. 
report that de novo, cell-intrinsic, BH4 synthesis is necessary for T cells to undergo clonal 
expansion. The initial prompt was the observation that activated T cells expressed GTP 
cyclohydrolase I (GCH1), the first step in BH4 synthesis 2. Gch1-deficient mice were generated 
and activated T cells from these mice exhibited profound proliferative defects in vitro and in vivo, 
confirming that T cell-intrinsic BH4 synthesis was required for efficient T cell licensing. This 
proliferative defect was highly selective for T cells, as Gch1 ablation did not impact development 
of T and B lymphocytes or the ability of B cells and regulatory T cells (Treg cells) to acquire 
effector functions on activation.  
The potential clinical significance of BH4 emerged from mouse models of inflammatory colitis, 
allergy and autoimmune syndromes. In each model, inflammatory infiltrates and disease 
severity were attenuated significantly due to defective clonal expansion of T cells lacking Gch1. 
However, selective Gch1 ablation did not impair the ability of T cells to make IL-17 and IFN-γ, 
two pro-inflammatory cytokines that mediate T cell effector functions and drive auto-
inflammatory diseases. It was not reported if Gch1 ablation impacted expression of perforin and 
granzyme, which mediate target cell killing. Intriguingly, experimental autoimmune encephalitis 
(EAE), a popular mouse model of multiple sclerosis (MS), followed normal kinetics for two 
weeks after disease induction, irrespective of the ability of T cells to make BH4, Thus, the ability 
to make BH4 was not essential to drive EAE onset or to maintain disease for 6 weeks, implying 
that effector T cells do not induce or maintain EAE. However, intrinsic BH4 synthesis by T cells 
was required for EAE severity to increase progressively after disease onset. It is unclear from 
the data presented if a delayed role for BH4 synthesis in T cells also manifested in the colitis 
and allergy models. Collectively, these findings reveal that BH4 synthesis is necessary for 
activated T cells to expand but BH4 is not required for T cells to acquire weapons of destruction.  
The finding that T cells must make BH4 to undergo clonal expansion identifies a potential 
‘Achilles’ heel’ that might be exploited for clinical benefit. Accordingly, the study authors show 
that inhibiting BH4 synthesis attenuated T cell responses, while boosting BH4 synthesis 
potentiated T cell responses. A new drug (QM385) was developed to inhibit sepiapterin 
reductase (SPR), the terminal enzyme in the BH4 synthesis pathway. As expected, QM385 
reduced clonal expansion of activated mouse and human T cells and attenuated inflammatory 
responses and disease severity in the allergy model. On the other hand, enhancing Gch1 
expression increased T cell clonal expansion and increased T cell-mediated inflammation and 
disease severity in the allergy and colitis models, consistent with the notion that BH4 synthesis 
boosts destructive T cell immunity in these models. Enhanced Gch1 expression in mice also 
conferred greater resistance to tumor growth and administering BH4 to mice bearing 
established (albeit small) tumors attenuated subsequent tumor growth. These studies identify 
the BH4 synthesis pathway as a promising target to manipulate T cell immunity for clinical 
benefit in a range of diseases.  
Further insights into the molecular mechanism of BH4-mediated licencing of T cells emerged 
from gene expression profiling of activated Gch1-deficient T cells. Enzymes involved in iron 
metabolism were affected by Gch1 ablation. Mitoferrin, a mitochondrial iron transporter, was up-
regulated prominently in T cells lacking Gch1, whereas iron levels were reduced in activated T 
cells lacking intact Gch1 genes. These findings implied that Gch1 mobilizes iron required for 
normal mitochondrial respiration, a notion borne out by studies showing that ATP synthesis was 
attenuated and glycolysis was augmented in T cells from Gch1-deficient mice. Moreover, 
mitochondrial respiration and oxygen consumption were lower in T cells unable to synthesize 
BH4 due to defective mitochondrial electron transport linked to imbalance in cytochrome c redox 
states and consequent elevated production of reactive oxygen species (ROS). These defects 
were corrected by adding BH4 or reduced cytochrome c to Gch1-deficient T cells. Taken 
together, these studies suggest that BH4 maintains iron homeostasis needed for mitochondrial 
respiration in activated T cells. 
In an intriguing aside Cronin et al. mention a link between BH4 synthesis and tryptophan (Trp) 
metabolism, which impacts immunologic and neurologic processes. Trp catabolism suppresses 
T cell immunity via the kynurenine (Kyn) pathway, which is initiated by indoleamine 2,3 
dioxygenase (IDO) and tryptophan 2,3 dioxygenase (TDO). Elevated IDO and TDO activity 
suppresses T cell immunity in a range of chronic inflammatory diseases, including cancers, 
allergic and autoimmune syndromes 3,4. Cells expressing IDO or TDO produce bioactive Trp 
catabolites that suppress immunity and cause neurologic dysfunction. For example, Kyn and 
other downstream Trp catabolites suppress T cell immunity, though molecular mechanisms of T 
cell suppression remain controversial 3. Cronin et al. report that Kyn treatment inhibited SPR 
activity in T cells and that adding BH4 overcame the T cell suppressive effects of adding Kyn to 
restore T cell proliferation and reduce ROS production. Xanthurenic acid (XA) is a Trp catabolite 
made downstream of Kyn and XA is a potent SPR inhibitor 5, prompting the suggestion that XA 
might mediate the T cell suppressive effects of Kyn (Fig. 1). If verified, the Kyn pathway might 
be a natural regulator of BH4 synthesis in T cells, offering a potential new mechanism to explain 
the T cell suppressive effects of IDO and TDO activity. These findings also imply that the T cell 
stimulatory effects of IDO inhibitors, currently under intense scrutiny as potential drugs to boost 
anti-tumor immunity in cancer patients 6, may in part arise due to blockade of XA synthesis, 
thereby releasing the brakes on BH4-mediated clonal expansion of effector T cells (Fig. 1).  
Though potential links between the BH4 and Kyn pathways cited above are plausible they 
raise new questions. For example, access to amino acids is essential for T cell licensing, as 
amino acid transporters are induced in activated T cell and loss of amino acid transporter 
functions blocks T cell clonal expansion and impairs development of malignant T cell leukemias 
7,8. In particular, T cells are sensitive to Trp depletion since the ribosomal amino acid sensors 
GCN2 and mTOR block T cell clonal expansion if IDO and TDO are active 3. Tryptophan 
hydroxylase-1 (TPH1) also consumes Trp as the obligate substrate to make the monoamine 
neurotransmitter serotonin (5-hydroxytryptamine, 5HT). Intriguingly, BH4 is an essential TPH1 
co-factor and TPH1 activity was necessary for mast cells to suppress T cell immunity in mouse 
models of transplant tolerance, tumor growth and EAE via a mechanism independent of 5HT 
synthesis 9. These observations beg the question of whether de novo BH4 biosynthesis in mast 
cells might be necessary to suppress T cell immunity that protects tumors, or transplanted and 
healthy tissues from destruction in these models. Other questions relate to links between 
elevated Kyn pathway activity during chronic inflammation and neurologic dysfunction leading to 
increased pain sensitivity, chronic fatigue and neurologic depression 10,11. Clearly, the BH4, 5HT 
and Kyn pathways are a confluence of metabolic processes that regulate immunologic and 
neurologic processes in many chronic inflammatory conditions, which may be exploited for 
therapeutic benefit. As evidenced by ongoing efforts to develop IDO and TDO inhibitors as 
treatments to block Trp catabolism in cancer patients6, metabolic pathways underpinning 
immune processes provide a growing number of new targets for immunotherapy. It is also likely 
that common neurologic comorbidities arising during disease progression or in response to 
therapy may be rooted in metabolic changes in BH4, 5HT and Kyn pathway activity.  
In summary, Cronin et al. identify BH4 synthesis as a metabolic ‘Achilles’ heel’ that might be 
exploited to prevent T cells from acquiring storm trooper status as they transit through the 
immunologic licensing process. Their study also raises intriguing links between BH4 and 5HT 
synthesis and the Kyn pathway that might have wide ranging implications for understanding how 
immune balance and neurologic comorbidities manifest in many chronic inflammatory diseases 
and how immunotherapies modify these linked metabolic pathways. In light of these reminders 
of the critical importance of metabolic controls it may be worth remembering Napoleon’s alleged 
quote that, ‘an army marches on its stomach’. 
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 Figure 1. BH4 plays a key role in T cell licensing. Cronin et al., report that de novo BH4 synthesis is 
essential for activated T cells to expand and acquire effector functions. BH4 regulates iron metabolism 
needed for mitochondrial (Mito) functions that support T cell licensing. Indoleamine 2,3 dioxygenase (IDO) 
activity inhibits BH4 synthesis by generating the tryptophan (Trp) catabolite xanthurenic acid (XA), which 
inhibits sepiapterin reductase (SPR) activity to block T cell licensing. BH4 is also a cofactor for TPH, the 
first step in serotonin (5HT) synthesis. 
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